Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.

Current research in translational medicine - 1 Jan 2000

Nicod Clémentine, da Rocha Mathieu Neto, Warda Walid, Roussel Xavier, Haderbache Rafik, Seffar Evan, Trad Rim, Bouquet Lucie, Goncalves Mathieu, Bosdure Léa, Laude Marie-Charlotte, Guiot Mélanie, Ferrand Christophe, Deschamps Marina

Abstract excerpt

PURPOSE OF THE STUDY: The use of chimeric antigen receptor (CAR)-T cells has demonstrated excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (ATMP) status and good manufacturing practice (GMP) of CAR-T cells require particular conditions of production performed in a pharmaceutical establishment. Our team developed a new medical drug candidate for acute myeloid leukemia (AML), a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy, Adoptive
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to T-Lymphocytes

Source

Identifiers

PMID: 36773434
DOI: 10.1016/j.retram.2023.103385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.PMID 36773434Read ↗

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.Semantic proximity Read ↗

Automated GMP-Compatible Production of Universal CAR Tregs for Organ-Targeted Tolerance InductionSemantic proximity Read ↗

An open CAR-T single-cell atlas to enable in-depth characterization and rational engineering of CAR-T productsSemantic proximity Read ↗

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read ↗

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaSemantic proximity Read ↗

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read ↗

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Semantic proximity Read ↗

Rapacaspase-9-based Suicide Gene Applied to the Safety of Il-1rap Car-t CellsSemantic proximity Read ↗

RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cellsSemantic proximity Read ↗

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.